ArticleSurgical endoscopy2025
An easily machine learning-based tool for preliminary risk assessment of microvascular invasion in hepatocellular carcinoma.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMicrovascular invasion (MVI) is a crucial risk factor for postoperative recurrence in patients with hepatocellular carcinoma (HCC). Accurate preoperative assessment of MVI and appropriate resection margins (RM) could reduce recurrence rates of HCC.
methodsA total of 1651 eligible patients who underwent liver resection between January 1, 2018 and June 30, 2023 were retrospectively collected. They were divided into the training (830 patients), the validation (356 patients), and the separate internal temporal test (465 patients) sets. The readily available features are emphasized in this study (including basic clinical and hematological features). Lasso regression was used for features' selection. Multivariate logistic regression and restricted cubic splines were conducted to evaluate the associations between the selected features and MVI. Seven machine learning algorithms were employed to constructed predictive model.
resultsThe preoperative factors associated with MVI were age, thrombin time, international normalized ratio (INR), aspartate aminotransferase, direct bilirubin, alpha-fetoprotein, mean corpuscular volume, multi tumor, tumor size, and fibrinogen/INR. Incorporating these factors, the LightGBM model achieved good predictive efficacy than other models, with the AUCs of 0.84 (95% CI: 0.81, 0.87) and 0.78 (95% CI: 0.73, 0.83) in the training and validation sets. This model also maintained satisfactory prediction in the separate temporal test set (AUC: 0.78, 95% CI: 0.74, 0.83) with good calibration and clinical net benefit. In addition, the recurrence-free survival (RFS) could be significantly stratified in the MVI high-risk and low-risk groups by this model, and the RFS of patients with wide RM was higher than that of patients with narrow RM in the high-risk MVI group (< 1 cm).
conclusionThe LightGBM model using readily available features was constructed to rapidly assess the risk of MVI in HCC patients. Based on this model, we developed a web-independent calculator for clinicians to easily operate the proposed model.
Indexed as
Identifiers
40866589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.